Sangamo in $3 billion gene-editing deal with Gilead

(Reuters) - U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.

Source: Reuters: Health - February 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news